Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer.
Hill
S M
SM
Department of Anatomy, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
Teplitzky
S
S
Ram
P T
PT
Kiefer
T
T
Blask
D E
DE
Spriggs
L L
LL
Eck
K M
KM
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D008550:Melatonin / Q000627:therapeutic use* / Q000633:toxicity; D011956:Receptors, Cell Surface / Q000032:analysis; D018160:Receptors, Cytoplasmic and Nuclear / Q000032:analysis; D044094:Receptors, Melatonin; D018168:Receptors, Retinoic Acid / Q000032:analysis; D014212:Tretinoin / Q000627:therapeutic use* / Q000633:toxicity; D014407:Tumor Cells, Cultured
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin; D018168:Receptors, Retinoic Acid; D014212:Tretinoin; D008550:Melatonin